Hysobrid 750 Tablet contains Sultamicillin tosilate 750 mg, a combination antibiotic consisting of ampicillin and sulbactam in a prodrug form that enhances oral bioavailability. It is indicated for the treatment of various bacterial infections caused by susceptible organisms, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections. Sultamicillin works by inhibiting bacterial cell wall synthesis through the ampicillin component, while sulbactam acts as a beta-lactamase inhibitor, preventing the degradation of ampicillin by beta-lactamase-producing bacteria, thereby extending its spectrum of activity. This dual mechanism makes Hysobrid 750 effective against a broad range of gram-positive and gram-negative pathogens, including beta-lactamase-producing strains. The tablet should be administered orally, preferably on an empty stomach to maximize absorption. Dosage and duration of therapy depend on the severity and type of infection, as well as patient-specific factors such as renal function. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and rash. Caution is advised in patients with a history of penicillin allergy. Hysobrid 750 should be used under medical supervision to ensure appropriate use and to minimize the risk of resistance development.